H.C. Wainwright lowered the firm’s price target on Zynex (ZYXI) to $8 from $15 and keeps a Buy rating on the shares. The company reported a top- and bottom-line miss in Q1, the analyst tells investors in a research note. The firm lowered 2025 revenue projection until the payor issue with Tricare is resolved.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYXI: